Your browser doesn't support javascript.
loading
Resistance against two lytic phage variants attenuates virulence and antibiotic resistance in Pseudomonas aeruginosa.
García-Cruz, Juan Carlos; Rebollar-Juarez, Xareni; Limones-Martinez, Aldo; Santos-Lopez, Cristian Sadalis; Toya, Shotaro; Maeda, Toshinari; Ceapa, Corina Diana; Blasco, Lucia; Tomás, María; Díaz-Velásquez, Clara Estela; Vaca-Paniagua, Felipe; Díaz-Guerrero, Miguel; Cazares, Daniel; Cazares, Adrián; Hernández-Durán, Melisa; López-Jácome, Luis Esaú; Franco-Cendejas, Rafael; Husain, Fohad Mabood; Khan, Altaf; Arshad, Mohammed; Morales-Espinosa, Rosario; Fernández-Presas, Ana María; Cadet, Frederic; Wood, Thomas K; García-Contreras, Rodolfo.
Afiliación
  • García-Cruz JC; Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.
  • Rebollar-Juarez X; Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.
  • Limones-Martinez A; Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.
  • Santos-Lopez CS; Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.
  • Toya S; Universidad Univer Milenium, Toluca de Lerdo, Mexico.
  • Maeda T; Department of Biological Functions Engineering, Graduate School of Life Science and Systems Engineering, Kyushu Institute of Technology, Kitakyushu, Japan.
  • Ceapa CD; Department of Biological Functions Engineering, Graduate School of Life Science and Systems Engineering, Kyushu Institute of Technology, Kitakyushu, Japan.
  • Blasco L; Microbiology Laboratory, Chemistry Institute, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.
  • Tomás M; Microbiología Traslacional y Multidisciplinar (MicroTM), Instituto de Investigación Biomédica (INIBIC), Universidad de A Coruña (UDC), A Coruña, Spain.
  • Díaz-Velásquez CE; Servicio de Microbiología, Hospital A Coruña (CHUAC), Universidad de A Coruña (UDC), A Coruña, Spain.
  • Vaca-Paniagua F; Microbiología Traslacional y Multidisciplinar (MicroTM), Instituto de Investigación Biomédica (INIBIC), Universidad de A Coruña (UDC), A Coruña, Spain.
  • Díaz-Guerrero M; Servicio de Microbiología, Hospital A Coruña (CHUAC), Universidad de A Coruña (UDC), A Coruña, Spain.
  • Cazares D; Laboratorio Nacional en Salud, Diagnóstico Molecular y Efecto Ambiental en Enfermedades Crónico-Degenerativas, Facultad de Estudios Superiores (FES) Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla de Baz, Estado de México, Mexico.
  • Cazares A; Laboratorio Nacional en Salud, Diagnóstico Molecular y Efecto Ambiental en Enfermedades Crónico-Degenerativas, Facultad de Estudios Superiores (FES) Iztacala, Universidad Nacional Autónoma de México, Tlalnepantla de Baz, Estado de México, Mexico.
  • Hernández-Durán M; Subdirección de Investigación Básica, Instituto Nacional de Cancerología, Ciudad de México, Mexico.
  • López-Jácome LE; Departamento de Microbiología y Parasitología, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.
  • Franco-Cendejas R; Department of Biology, University of Oxford, Oxford, United Kingdom.
  • Husain FM; Parasites and Microbes Programme, Wellcome Sanger Institute, Hinxton, United Kingdom.
  • Khan A; Laboratorio de Microbiología Clínica, División de Infectología, Instituto Nacional de Rehabilitación, Luis Guillermo Ibarra Ibarra, Mexico, Mexico.
  • Arshad M; Laboratorio de Microbiología Clínica, División de Infectología, Instituto Nacional de Rehabilitación, Luis Guillermo Ibarra Ibarra, Mexico, Mexico.
  • Morales-Espinosa R; Departamento de Biología, Facultad de Química, Universidad Nacional Autónoma de México (UNAM), Mexico City, Mexico.
  • Fernández-Presas AM; Subdirección de Investigación Biomédica, Instituto Nacional de Rehabilitación Luis Guillermo Ibarra Ibarra, Mexico, Mexico.
  • Cadet F; Department of Food Science and Nutrition, King Saud University, Riyadh, Saudi Arabia.
  • Wood TK; Department of Pharmacology, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
  • García-Contreras R; Dental Health Department, College of Applied Medical Sciences, King Saud University, Riyadh, Saudi Arabia.
Front Cell Infect Microbiol ; 13: 1280265, 2023.
Article en En | MEDLINE | ID: mdl-38298921
ABSTRACT

Background:

Bacteriophage therapy is becoming part of mainstream Western medicine since antibiotics of clinical use tend to fail. It involves applying lytic bacteriophages that self-replicate and induce cell lysis, thus killing their hosts. Nevertheless, bacterial killing promotes the selection of resistant clones which sometimes may exhibit a decrease in bacterial virulence or antibiotic resistance.

Methods:

In this work, we studied the Pseudomonas aeruginosa lytic phage φDCL-PA6 and its variant φDCL-PA6α. Additionally, we characterized and evaluated the production of virulence factors and the virulence in a Galleria mellonella model of resistant mutants against each phage for PA14 and two clinical strains.

Results:

Phage φDCL-PA6α differs from the original by only two amino acids one in the baseplate wedge subunit and another in the tail fiber protein. According to genomic data and cross-resistance experiments, these changes may promote the change of the phage receptor from the O-antigen to the core lipopolysaccharide. Interestingly, the host range of the two phages differs as determined against the Pseudomonas aeruginosa reference strains PA14 and PAO1 and against nine multidrug-resistant isolates from ventilator associated pneumonia.

Conclusions:

We show as well that phage resistance impacts virulence factor production. Specifically, phage resistance led to decreased biofilm formation, swarming, and type III secretion; therefore, the virulence towards Galleria mellonella was dramatically attenuated. Furthermore, antibiotic resistance decreased for one clinical strain. Our study highlights important potential advantages of phage therapy's evolutionary impact that may be exploited to generate robust therapy schemes.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Bacteriófagos / Fagos Pseudomonas / Terapia de Fagos / Mariposas Nocturnas Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Front Cell Infect Microbiol Año: 2023 Tipo del documento: Article País de afiliación: México

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Bacteriófagos / Fagos Pseudomonas / Terapia de Fagos / Mariposas Nocturnas Tipo de estudio: Prognostic_studies Límite: Animals Idioma: En Revista: Front Cell Infect Microbiol Año: 2023 Tipo del documento: Article País de afiliación: México